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ess: bargagli2@unisi.itSummary The aim of the study was to investigate the upper respiratory tract as a
site of extrapulmonary sarcoidosis. Diagnosis of sarcoidosis with upper respiratory
tract involvement was performed on the basis of clinical, laboratory, radiographic
and histological evidence and by excluding other granulomatous diseases in eight
patients followed by the Sarcoidosis Regional Reference Centre pneumologists in
collaboration with an experienced ENT specialist at Siena University. In five cases,
sarcoidosis was localized in the parotid glands, in the other three subjects larynx,
nasopharynx and nose were involved. In four patients parotid gland, nasopharynx
and upper respiratory tract mucous membrane involvement was the only clinical
manifestation at onset of the disease.
Upper respiratory tract involvement should be suspected in all patients with
systemic sarcoidosis and in patients with persistent upper respiratory tract
symptoms of unknown cause. What a general practitioner should do as not to miss
SURT is underlined. Interdisciplinary management and collaboration are of
paramount importance for rapid diagnosis and to avoid the possible complications
of this form.
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In sarcoidosis upper respiratory tract involvement
(SURT) is uncommon, occurring in approximately 6%
of patients. The most characteristic and earliest
detectable site is the parotid gland, that encom-
pass a wide variety of clinical syndromes; whereas
larynx, nasopharynx and nose localization are less
frequent and more difficult to identify.1–7 The large
epidemiological study, A.C.C.E.S.S.3 recently per-
formed in the USA, reported ear, nose and throat
involvement in 22 (2.3%) out of 736 S patients
enrolled; in only three it was limited to the
nasopharynx.
Diagnosis of SURT without typical lung involve-
ment requires a compatible clinical pattern,
histopathologic confirmation of noncaseating gran-
ulomas, and exclusion of other diseases with similar
histologic or clinical manifestations.1,8 Diffe-
rential diagnosis therefore includes tuberculosis,
histoplasmosis, blastomycosis, coccidiomycosis,
syphilis, actinomycosis, malignant neoplasm, carti-
laginous tumours, Wegener’s granulomatosis and
amyloidosis.1,6,8
Here we report the clinical findings of eight
patients with histologically proven SURT and de-
scribe four of them in greater detail, to show four
different types of involvement. In these patients
sarcoidosis was diagnosed on the basis of
the histology of upper respiratory tract biopsy
specimens.Patients
The subjects were eight patients with SURT: five
women and three men ranging in age from 22 to 66
years (mean age 51 years). Their clinical features
are summarized in Table 1. In five patients STable 1 Clinical features.
Case
no.
Sex Age
(yr)
Chest
radiological
stage
ACE
(UI/ml/min)
% BAL
lymph
1 M 44 1 74 m n.d
2 F 66 1 49 73.5
3 F 62 2 67 m 50
4 F 64 3 105 m 55
5 F 39 1 56 m n.d.
6 M 22 2 62 m 45.5
7 F 62 2 67 m 43
8 M 49 3 n.d. 32involved the parotid glands, and in three the
larynx, nasopharynx and nose. In all patients, SURT
was diagnosed according to histopathological cri-
teria. In four cases, described in more detail below,
biopsies of parotid glands, nasopharynx, larynx and
nasal mucosa enabled diagnosis of S. In these
subjects the upper respiratory tract manifestations
were the only clinical evidence at the onset of the
disease. All patients with parotid gland involve-
ment had bilateral localization, more evident in
the left gland.
Case 1: A 22-year-old man showed a single
clinical sign at the onset of the disease, namely
bilateral parotid enlargement (more evident on the
left side) associated with fever, dry mouth and
sweating. Biopsy of the left parotid gland (Fig. 1)
led to a diagnosis of S, subsequently confirmed by
radiographic findings (stage I in chest X-ray) and
liver biopsy. A long course of steroid therapy was
maintained. Chest X-ray became normal and the
patient is now well. The parotid glands show
minimal ultrasonographic evidence of non-homo-
genous parenchyma.
Case 2: A 62-year-old woman had systemic S
(lungs, hilar–mediastinal lymph nodes, ribs) and
involvement of the salivary glands and larynx,
confirmed by histological examination. At the onset
the patient complained of dysphagia with solids and
liquids, persistent cough, retrosternal pain and
exertion dyspnea. Chest X-ray showed stage II
sarcoidosis, BAL documented lymphocytic alveolitis
with a CD4/CD8 ratio of 7. ACE and lysozyme serum
levels were elevated, together with IgM immuno-
complexes. The patient was treated with scalar
dose of prednisone (starting at 30mg/day) and
achieved radiological improvement. One year later,
she complained of oral discomfort with impaired
sense of taste. Parotid sialography showed reduced
volume of the glands and rare peripheral duct
ramifications. Biopsy of the labial mucosa showedocytes
CD4/CD8
ratio
SURT
localization
SURT
biopsy
Therapy
n.d. Parotid + Steroids
5.8 Parotid + Steroids
10 Larynx + Steroids
5 Parotid + Steroids
n.d. Rinopharinx + Steroids
6 Parotid + Steroids
2.8 Parotid + Steroids
2.3 Nose + Surgery
Steroids
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Figure 2 Biopsy of the vocal fold with sarcoid lesion
(hematoxylin–eosin,  10).
Figure 1 Biopsy of the right parotid gland. Note non-
necrotizing epithelioid granuloma (hematoxylin–eosin,
 20).
Figure 3 Nasal pyramid deformation in Case 4.
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with S. Dysphonia and pyretic pharyngodynia
manifested about 2 years later, together with
relapse of S (chest X-ray stage II). ENT examination
revealed marked hypomobility of the right hemi-
larynx with swelling of the right false vocal cord
and laryngeal vestibule. Biopsy (Fig. 2) showed
Ziehl–Nielsen-negative, epithelioid giant-cell granu-
lomatosis and a subsequent bronchial biopsy con-
firmed these histopathological findings. BAL showed
lymphocytosis (59%) with a CD4/CD8 ratio of 3.1.
The patient was treated with scalar doses of
prednisone starting at 40mg/day and achieved
significant clinical and radiological improvement.
Three months later, while on 20mg/day predni-
sone, the patient complained of dysphonia and
purulent discharge. Routine laboratory tests re-
vealed ESR 65mm/1 h, CRP 5.7mg/dl, microhema-
turia, and hypogammaglobulinemia. Chest X-ray
showed non-homogeneous parenchymal infiltrate
with cavity lesions. Mycobacterium tuberculosis
complex was found in sputum. After several months
of antitubercular and low dose steroid therapy, the
patient’s condition improved considerably and
dysphonia disappeared. Chest X-ray showed an
absence of tubercular lesions but relapse of S
(stage III) associated with an increase in serum
levels of ACE and lysozyme. After 11 years the
disease is still in active phase and the patient
continues low dose steroid therapy.
Case 3: A 39-year-old female complained of
chronic maxillary sinusitis, documented by CT.
ENT examination showed mucosal swelling occlud-
ing 1/3 of the nasopharyngeal cavum. Nasophar-
yngeal biopsy showed granulomas compatible with
S. Chest CT revealed mediastinal lymphoadenopa-
ties. Corticosteroid treatment was started and
continues. The nasopharyngeal swelling decreased
but has not disappeared.Case 4: A 49-year-old male patient complained of
recurring dacryocystitis in the right eye and nasal
obstruction. Chest X-ray was normal. ENT examina-
tion showed a deformation of the nasal pyramid
considered post-traumatic (Fig. 3) with substenotic
deviation of the nasal septum, marked rhinorrhea
and clinical evidence of maxillary sinusitis. After
unsuccessful pharmacological treatment with local
and systemic antibiotics, the patient underwent
septoplasty, inferior turbinoplasty and bilateral
endoscopic enlargement of the natural maxillary
ostium. Histological examination of biopsies of
mucosa of the nasal septum and inferior turbinates
indicated S. Chest CT subsequently showed diffuse
bilateral nodular opacities. BAL indicated lympho-
cytic alveolitis with a high CD4/CD8 ratio. Trans-
bronchial biopsy was positive for epithelioid
granulomas, in line with the initial diagnosis. The
patient was treated with prednisone, starting at
0.5mg/kg, with much improvement in symptoms.
Long-term steroid treatment was undertaken.
Nasal symptoms and recurrent dacryocystitis have
now disappeared. Retrospective evaluation of nasal
morphology makes nasal bone sarcoid involvement
more likely than trauma.
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Diagnosis of upper respiratory tract involvement in
sarcoidosis may require the co-operation of pneu-
mologists and ENT specialists, as demonstrated in
the cases described here.
Case 1 with parotid gland involvement represents
the most frequent and easily diagnosed localization
of SURT. Parotid gland biopsy made diagnosis
possible. This kind of biopsy is seldom indicated,
though the need to confirm suspected S may justify
it, particularly if minor salivary gland biopsy is
negative or inconclusive. Case 2 was particularly
difficult to diagnose because of the rarity of sarcoid
vocal cord involvement and of subsequent tuber-
cular lung complications. The histopathology of the
laryngeal lesion, recovery with anti-tubercular
treatment and persistence of steroid sensitive
laryngeal involvement confirmed the diagnosis of
SURT. In this localization, symptoms may be mild,
but supraglottal granuloma may cause severe air-
way obstruction.
The third patient had nasopharyngeal involve-
ment. This localization is rare, especially in
children and difficult to suspect.9 The fourth case
had aggressive involvement of the lachrymal glands
and sinonasal tract without other symptoms. The
saddle nose deformity, reported as post-traumatic,
was actually due to nasal cartilage localization of
sarcoidosis. Septal perforation, nasal bone osteo-
porosis or destruction and cartilage destruction
with nasal deformity have been described in
patients with severe disease.10,11 Braun and col-
leagues 12 recently reported 15 cases of sinonasal S
and proposed two diagnostic criteria, namely poor
response to conventional treatments and radiolo-
gical evidence of rhinosinusitis, often with nodules
on the septum and turbinates.
The general practitioner should obtain an accu-
rate clinical history and examine all patients with
chronic undiagnosed and progressive upper airway
involvement (particularly sarcoidosis patients). If
he suspects SURT, he should refer the patient to an
ENT specialist expert in S. The ENT specialist
examining the patient for the first time must
carefully assess any chronic rhinosinusitis that
responds poorly to conventional treatment, and
examine the mucosa of the nasal septum, turbi-
nates and nasopharynx for abnormal crusting,
swelling or nodules. Diagnosis of SURT is particu-
larly difficult in the absence of symptoms or when
upper respiratory involvement is the first manifes-
tation, because this site is rare and differential
diagnosis with respect to many other causes is
difficult. In these patients, a panel of tests (X-rays,
CT scan) and a biopsy are necessary to confirmdiagnosis and evidence of other organ localization
should be sought.6,13–16
Early recognition of SURT helps prevent severe
complications, such as upper airway obstruction in
laryngeal S, anosmia and erosion of septal cartilage
with nasal collapse and deformity in nasal involve-
ment, facial palsy in cranial nerve involvement,
and persistent enlargement of the parotid glands
with dry mouth in salivary gland involvement.
There have been no studies in large series of
SURT patients as to the effectiveness of pharma-
cological treatment, although international guide-
lines suggest that systemic or intralesional
corticosteroids are indicated when critical organs
are involved or when S is severe.1 Topical steroids
alone may be effective in SURT and intralesional
steroid treatment has been proposed, particularly
for patients with laryngeal S.3,17 In chronic patients
with symptomatic SURT, steroid treatment is gen-
erally used. Immunosuppressive and cytotoxic
drugs, such as methotrexate, azathioprine and in
some cases cyclophosphamide, have been adminis-
tered in difficult cases.6,18,19 In patients with
chronic refractory sarcoidosis, new anticytokine
agents that block TNF have been proposed. These
therapies include pentoxifylline, thalidomide and
more recently infliximab.6,18,20 Use of thalidomide
is limited by its toxicity and more clinical control
trials are necessary to confirm its efficacy.18
Infliximab is a chimeric antibody, which specifically
inhibits TNF alpha.21 It has been successfully used
in patients with persistent symptomatic sarcoido-
sis.6,19,20 In patients 2 and 4, treatment with
infliximab was considered, but it was not given
due to pulmonary tuberculosis lesions and dacryo-
cystitis, respectively. Sharma reported the effec-
tiveness of antimalarial agents (such as chloroquine
and hydroxychloroquine) in treating selected pa-
tients with sarcoidosis.6,22 Surgery is useful for
intranasal management of complication and airway
obstruction. Septoplasty may be complicated by
septal perforation. We have no personal experience
with radiotherapy in laryngeal S, but failures seem
to outnumber successes.23
In conclusion, the present experience suggests
that collaboration between pneumologists and ENT
specialists is necessary for early diagnosis of SURT
and to reduce its complications.References
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